Literature DB >> 20479083

Staphylococcal superantigen-like protein 5 inhibits matrix metalloproteinase 9 from human neutrophils.

Saotomo Itoh1, Eri Hamada, Go Kamoshida, Kana Takeshita, Teruaki Oku, Tsutomu Tsuji.   

Abstract

Staphylococcal superantigen-like proteins (SSLs) constitute a family of exoproteins exhibiting structural similarities to superantigens and enterotoxins but no superantigenic activity. In this article, we present evidence that SSL5 specifically binds to matrix metalloproteinase 9 (MMP-9) and inhibits its enzymatic activity. When human neutrophil cell lysate was applied to recombinant His-tagged SSL5 conjugated to Sepharose, the bound fraction gave a major band of approximately 100 kDa in SDS-polyacrylamide gel electrophoresis. This protein was identified as the proform of MMP-9 (proMMP-9) by peptide mass fingerprinting analysis. The recombinant SSL5-Sepharose also bound to proMMP-9 secreted by interleukin 8 (IL-8)-stimulated neutrophils and HT1080 fibrosarcoma cells. Surface plasmon resonance analysis revealed that recombinant SSL5 bound to proMMP-9 with rather high affinity (dissociation constant [K(D)] = 1.9 nM). Recombinant SSL5 was found to effectively inhibit MMP-9-catalyzed hydrolysis of gelatin and a synthetic fluorogenic peptide in a noncompetitive manner (K(i) = 0.097 nM), as assessed by zymography and the fluorescence quenching method. Finally, the transmigration of neutrophils across Matrigel basement membranes in response to N-formyl-methionyl-leucyl-phenylalanine (FMLP) was suppressed by the presence of recombinant SSL5. We discuss possible roles that SSL5 may play in immune evasion of staphylococci by inhibiting MMP and interfering with leukocyte trafficking.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20479083      PMCID: PMC2897379          DOI: 10.1128/IAI.00178-10

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria.

Authors:  Ries Langley; Bruce Wines; Natasha Willoughby; Indira Basu; Thomas Proft; John D Fraser
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

2.  Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases.

Authors:  Suzan H M Rooijakkers; Maartje Ruyken; Anja Roos; Mohamed R Daha; Julia S Presanis; Robert B Sim; Willem J B van Wamel; Kok P M van Kessel; Jos A G van Strijp
Journal:  Nat Immunol       Date:  2005-08-07       Impact factor: 25.606

3.  Staphylococcal superantigen-like 5 binds PSGL-1 and inhibits P-selectin-mediated neutrophil rolling.

Authors:  Jovanka Bestebroer; Miriam J J G Poppelier; Laurien H Ulfman; Peter J Lenting; Cecile V Denis; Kok P M van Kessel; Jos A G van Strijp; Carla J C de Haas
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

Review 4.  Immune evasion by staphylococci.

Authors:  Timothy J Foster
Journal:  Nat Rev Microbiol       Date:  2005-12       Impact factor: 60.633

Review 5.  Role of PSGL-1 binding to selectins in leukocyte recruitment.

Authors:  R P McEver; R D Cummings
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

6.  Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.

Authors:  Y Tamura; F Watanabe; T Nakatani; K Yasui; M Fuji; T Komurasaki; H Tsuzuki; R Maekawa; T Yoshioka; K Kawada; K Sugita; M Ohtani
Journal:  J Med Chem       Date:  1998-02-12       Impact factor: 7.446

7.  Insights into mechanisms used by Staphylococcus aureus to avoid destruction by human neutrophils.

Authors:  Jovanka M Voyich; Kevin R Braughton; Daniel E Sturdevant; Adeline R Whitney; Battouli Saïd-Salim; Stephen F Porcella; R Daniel Long; David W Dorward; Donald J Gardner; Barry N Kreiswirth; James M Musser; Frank R DeLeo
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

8.  Matrix metalloproteinase-9 (gelatinase B) deficiency leads to increased severity of Staphylococcus aureus-triggered septic arthritis.

Authors:  Ann-Marie Calander; Sofie Starckx; Ghislain Opdenakker; Philip Bergin; Marianne Quiding-Järbrink; Andrej Tarkowski
Journal:  Microbes Infect       Date:  2006-03-29       Impact factor: 2.700

9.  Glycosylation of natural human neutrophil gelatinase B and neutrophil gelatinase B-associated lipocalin.

Authors:  P M Rudd; T S Mattu; S Masure; T Bratt; P E Van den Steen; M R Wormald; B Küster; D J Harvey; N Borregaard; J Van Damme; R A Dwek; G Opdenakker
Journal:  Biochemistry       Date:  1999-10-19       Impact factor: 3.162

10.  Gelatinase B/matrix metalloproteinase-9 contributes to cellular infiltration in a murine model of zymosan peritonitis.

Authors:  Elzbieta Kolaczkowska; Magdalena Chadzinska; Anna Scislowska-Czarnecka; Barbara Plytycz; Ghislain Opdenakker; Bernd Arnold
Journal:  Immunobiology       Date:  2006-02-03       Impact factor: 3.144

View more
  21 in total

1.  Staphylococcal superantigen-like protein 3 binds to the Toll-like receptor 2 extracellular domain and inhibits cytokine production induced by Staphylococcus aureus, cell wall component, or lipopeptides in murine macrophages.

Authors:  Ryosuke Yokoyama; Saotomo Itoh; Go Kamoshida; Takemasa Takii; Satoshi Fujii; Tsutomu Tsuji; Kikuo Onozaki
Journal:  Infect Immun       Date:  2012-06-04       Impact factor: 3.441

2.  Activation of matrix metalloproteinase-9 (MMP-9) by neurotensin promotes cell invasion and migration through ERK pathway in gastric cancer.

Authors:  Hafeza Akter; Min Park; Oh-Seung Kwon; Eun Joo Song; Won-Sang Park; Min-Jung Kang
Journal:  Tumour Biol       Date:  2015-02-28

Review 3.  Staphylococcal manipulation of host immune responses.

Authors:  Vilasack Thammavongsa; Hwan Keun Kim; Dominique Missiakas; Olaf Schneewind
Journal:  Nat Rev Microbiol       Date:  2015-09       Impact factor: 60.633

Review 4.  Pathogenesis of Staphylococcus aureus Bloodstream Infections.

Authors:  Lena Thomer; Olaf Schneewind; Dominique Missiakas
Journal:  Annu Rev Pathol       Date:  2016-02-25       Impact factor: 23.472

5.  Potentiation of tumor cell invasion by co-culture with monocytes accompanying enhanced production of matrix metalloproteinase and fibronectin.

Authors:  Go Kamoshida; Ayaka Matsuda; Risa Miura; Yuri Takashima; Arisa Katsura; Tsutomu Tsuji
Journal:  Clin Exp Metastasis       Date:  2012-09-29       Impact factor: 5.150

6.  Dependency of Experimental Autoimmune Encephalomyelitis Induction on MOG35-55 Properties Modulating Matrix Metalloproteinase-9 and Interleukin-6.

Authors:  Ji-Eun Seo; Mahbub Hasan; Joon-Seung Han; Nak-Kyoon Kim; Ji Eun Lee; Kang Mi Lee; Ju-Hyung Park; Ho Jun Kim; Junghyun Son; Jaeick Lee; Oh-Seung Kwon
Journal:  Neurochem Res       Date:  2015-10-13       Impact factor: 3.996

7.  Differences in humoral immune response between patients with or without nasal carriage of Staphylococcus aureus.

Authors:  H Ghasemzadeh-Moghaddam; W van Wamel; A van Belkum; R A Hamat; V K Neela
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-11-04       Impact factor: 3.267

8.  Evasion of Toll-like receptor 2 activation by staphylococcal superantigen-like protein 3.

Authors:  B W Bardoel; R Vos; T Bouman; P C Aerts; J Bestebroer; E G Huizinga; T H C Brondijk; J A G van Strijp; C J C de Haas
Journal:  J Mol Med (Berl)       Date:  2012-06-20       Impact factor: 4.599

9.  Identifying functional anti-Staphylococcus aureus antibodies by sequencing antibody repertoires of patient plasmablasts.

Authors:  Daniel R Lu; Yann-Chong Tan; Sarah Kongpachith; Xiaoyong Cai; Emily A Stein; Tamsin M Lindstrom; Jeremy Sokolove; William H Robinson
Journal:  Clin Immunol       Date:  2014-03-01       Impact factor: 3.969

10.  Modulation of matrix metalloproteinase-9 secretion from tumor-associated macrophage-like cells by proteolytically processed laminin-332 (laminin-5).

Authors:  Go Kamoshida; Takashi Ogawa; Jun Oyanagi; Hiroki Sato; Eriko Komiya; Shouichi Higashi; Kaoru Miyazaki; Tsutomu Tsuji
Journal:  Clin Exp Metastasis       Date:  2013-12-01       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.